Skinvisible and Cambrex Enter Into Agreement to Develop Acne Products



    



    New Series of Benzoyl Peroxide with Invisicare Formulations Available

    
    LAS VEGAS & RUTHERFORD, N.J., Jan. 22 /PRNewswire-FirstCall/ --
Skinvisible, Inc. (OTC Bulletin Board:   SKVI), the developers of Invisicare, a
patented polymer delivery system that enhances topical skincare products, and
Cambrex Corporation, (NYSE:   CBM) a leading provider of products and services
to the pharmaceutical industry, announced today that they have signed a joint
marketing and development agreement. The agreement provides for research and
development into acne formulations based on Skinvisible's Invisicare
technology and benzoyl peroxide (BPO) manufactured by Cambrex. In addition,
the two companies will share marketing responsibilities for the products that
are developed under this agreement.
    

    (Logo:  http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)

    (Logo:  http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO)

    
    "Invisicare is a technology that adds many advantages to active
ingredients. Our recent developments with Cambrex's BPO in strengths of 2.5%,
5% and 10% along with the BPO combination formulations we are developing, has
given us a whole new series of acne products to license worldwide," said Terry
Howlett, President and CEO of Skinvisible Pharmaceuticals. "We have proven
that we can control the release of active ingredients such as BPO with
Invisicare and this can result in use of less active ingredient, less
irritation and better efficacy. Additionally, Invisicare can hold ingredients
on the skin allowing acne sufferers to benefit from the treatment for a longer
period of time."  He added, "We are confident that our collaboration with
Cambrex will be beneficial to both parties as we have complementary
ingredients that when combined, benefit from each other."
    

    
    "Cambrex produces a high-grade benzoyl peroxide API that is made under
cGMP and which has a Drug Master File (DMF)," said Steve Klosk, President and
CEO of Cambrex Corporation. "This collaboration with Skinvisible will enable
us to provide our clients with technology-enhanced delivery options for our
BPO products. We are excited to have the opportunity to associate our API with
Skinvisible's innovative technology. We foresee that this value-added approach
is an advantage for our clients and acne patients."
    

    
    About Invisicare(R) - Invisicare is Skinvisible's patented polymer
delivery system that offers "life-cycle management" and unique enhancements
for topically delivered products. It is a combination of hydrophilic and
hydrophobic polymers that hold active ingredients on the skin for extended
periods of time resisting both wash-off and perspiration. Invisicare controls
the release of actives, reducing irritation and eliminating some costly
manufacturing processes. It is non-occlusive and allows for normal skin
respiration while protecting against environmental irritants. 
www.invisicare.com
    

    
    About Skinvisible Pharmaceuticals, Inc. - Skinvisible Pharmaceuticals is
a research-and-development company whose primary business objective is to
license its proprietary formulations with Invisicare(R) to pharmaceutical and
cosmeceutical companies as well as assisting companies in revitalizing or
enhancing their existing skin care products. Skinvisible receives a
combination of research and development, license, and royalties fees for the
life of the Invisicare patent.  www.skinvisible.com
    

    
    About Cambrex Corporation - Cambrex provides products and services to
accelerate the development and commercialization of small molecule
therapeutics including active pharmaceutical ingredients ("API"), advanced
intermediates, enhanced drug delivery, and other products for branded and
generic pharmaceuticals.  www.cambrex.com
    

    Skinvisible Pharmaceuticals, Inc. Forward-Looking Statements
    
    This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks and
uncertainties associated with an emerging company. Actual results could differ
materially from those projected in the forward looking statements as a result
of risk factors discussed in Skinvisible, Inc. reports on file with the U.S.
Securities and Exchange Commission (including, but not limited to, a report on
Form 10Q for the quarter ending September 30, 2008).
    

    CambrexCorporation Forward-Looking Statements
    
    This news release may contain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6
under the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding expected performance, especially expectations
with respect to sales, research and development expenditures, earnings per
share, capital expenditures, acquisitions, divestitures, collaborations, or
other expansion opportunities.  These statements may be identified by the fact
that words such as "expects", "anticipates", "intends", "estimates",
"believes" or similar expressions are used in connection with any discussion
of future financial or operating performance.  Any forward-looking statements
are qualified in their entirety by reference to the risk factors discussed in
the Company's periodic reports filed with the U.S. Securities and Exchange
Commission.  Any forward-looking statements contained herein are based on
current plans and expectations and involve risks and uncertainties that could
cause actual outcomes and results to differ materially from current
expectations including, but not limited to, global economic trends,
pharmaceutical outsourcing trends, competitive pricing or product
developments, government legislation or regulations (particularly
environmental issues), tax rate, interest rate, technology, manufacturing and
legal issues, including the outcome of outstanding litigation disclosed in the
Company's public filings, changes in foreign exchange rates, uncollectible
receivables, loss on disposition of assets, cancellation or delays in renewal
of contracts, lack of suitable raw materials or packaging materials, the
Company's ability to receive regulatory approvals for its products and the
accuracy of the Company's current estimates with respect to its earnings and
profits for tax purposes in 2007.  Any forward-looking statement speaks only
as of the date on which it is made, and the Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise.  New factors emerge from time to time
and it is not possible for the Company to predict which new factors will
arise.  In addition, we cannot assess the impact of each factor on the
Company's business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in
any forward-looking statements.
    

    
    For further details and a discussion of these and other risks and
uncertainties, investors and security holders are cautioned to review the
Cambrex 2007 Annual Report on Form 10-K, including the Forward-Looking
Statement section therein, and other subsequent filings with the U.S.
Securities and Exchange Commission, including Current Reports on Form 8-K. 
The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
    

    

    
    Corporate Contact
    Doreen McMorran, VP Business Development
    Skinvisible Pharmaceuticals, Inc.
    

    
    Phone: 702-433-7154
    Email: info@skinvisible.com
    

    
    Corporate Contact:
    Dan Giambattisto, VP Drug Delivery
    Cambrex Corporation
    

    
    Phone: 845-278-2370
    Email: dan.giambattisto@cambrex.com




    




For further information:

For further information: Doreen McMorran, VP Business Development of
Skinvisible Pharmaceuticals, Inc., +1-702-433-7154, info@skinvisible.com; or
Dan Giambattisto, VP Drug Delivery of Cambrex Corporation, +1-845-278-2370,
dan.giambattisto@cambrex.com Web Site: http://www.cambrex.com                
http://www.invisicare.com                 http://www.skinvisible.com

Organization Profile

SKINVISIBLE, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890